NCT07662213ClinicalTrials.gov

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.

Contatta questo studio

In breve

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering…

Fase 31200 partecipanti ricercati209 centri15 paesi

Categorie

Endocrino e metabolico68%Cardiovascolare32%

Registrato in 1 registro

ClinicalTrials.govNCT07662213Apri questa scheda su ClinicalTrials.govSincronizzato 2 settimane fa

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2026-06-23; recorded start 2026-07-06
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm15/15
Active-comparator control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 201 sites
Data monitoring committee0/7
No data monitoring committee stated
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,200 participants (target), run at 209 sites, across 15 countries.

How this score is built

Enrolment31/40
1,200 participants (target)
Site count25/25
201 sites
Country count12/15
15 countries
Planned duration7/10
Planned over about 23 months
Sponsor scale10/10
AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

Patologie

Type 2 Diabetes Mellitus

Idoneità

Idoneità
Sesso	Tutti
Età	18 Years – Nessun massimo
Volontari sani	No

Idoneità come riportata nel registro

Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * Severe congestive heart failure (NYHA IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studio	Interventistico
Fase	Fase 3
Assegnazione	Randomizzata
Modello di intervento	PARALLEL
Finalità principale	TREATMENT
Mascheramento	NONE (0)
Arruolamento	1200 partecipanti ricercati

Sponsor e collaboratori

AstraZeneca Sponsor

Bracci e interventi

ElecoglipronEXPERIMENTAL
Participants will receive elecoglipron dose XX mg administered orally once daily.
SemaglutideACTIVE_COMPARATOR
Participants will receive semaglutide dose XX mg administered orally once daily.

Interventi

Farmaco Elecoglipron
Elecoglipron is administered orally once daily.
Farmaco Semaglutide
Semaglutide is administered orally once daily.

Esiti misurati

Esito primario
Change from baseline in Hemoglobin A1c (HbA1c)
Orizzonte temporale Baseline to Week 52
Esito secondario
Percent change from baseline to Week 52 in body weight
Orizzonte temporale Baseline to Week 52
Esito secondario
Change from baseline to Week 52 in body weight (kg)
Orizzonte temporale Baseline to Week 52
Esito secondario
Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52
Orizzonte temporale Baseline to Week 52
Esito secondario
Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52
Orizzonte temporale Week 52
Esito secondario
Achieved HbA1c < 7% (53 mmol/mol) at Week 52
Orizzonte temporale Week 52
Esito secondario
Achieved ≥ 5% weight loss from baseline at Week 52
Orizzonte temporale Baseline to Week 52
Esito secondario
Change from baseline to Week 52 in Systolic Blood Pressure (BP) and Diastolic BP
Orizzonte temporale Baseline to Week 52

Date

Date
Data di inizio	6 luglio 2026 (effettiva)
Conclusione primaria	23 maggio 2028 (stimata)
Conclusione	23 maggio 2028 (stimata)
Prima pubblicazione	23 giugno 2026 (effettiva)
Ultimo aggiornamento	9 settembre 2026
Risultati pubblicati	Non indicato nella scheda del registro
Stato verificato l'ultima volta	maggio 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

51 centri stanno reclutando

Argentina

Argentina
Struttura	Città	Stato
Research Site	Buenos Aires	Non ancora in reclutamento
Research Site	Buenos Aires	In reclutamento
Research Site	Caba	Non ancora in reclutamento
Research Site	Ciudad de Buenos Aires	In reclutamento
Research Site	Rosario	Non ancora in reclutamento
Research Site	San Nicolás	Non ancora in reclutamento
Research Site	San Vicente	In reclutamento

Australia

Australia
Struttura	Città	Stato
Research Site	Botany	In reclutamento
Research Site	East Toowoomba	In reclutamento
Research Site	Fitzroy	Non ancora in reclutamento
Research Site	Heidelberg Heights	Non ancora in reclutamento
Research Site	Kingswood	Non ancora in reclutamento
Research Site	Melbourne	In reclutamento
Research Site	Parkville	In reclutamento
Research Site	Penrith	Non ancora in reclutamento
Research Site	St Leonards	In reclutamento

Brazil

Brazil
Struttura	Città	Stato
Research Site	Brasília	Non ancora in reclutamento
Research Site	Campinas	Non ancora in reclutamento
Research Site	Curitiba	Non ancora in reclutamento
Research Site	Natal	Non ancora in reclutamento
Research Site	Porto Alegre	Non ancora in reclutamento
Research Site	São José dos Campos	Non ancora in reclutamento
Research Site	São Paulo	Non ancora in reclutamento

Bulgaria

Bulgaria
Struttura	Città	Stato
Research Site	Plovdiv	In reclutamento
Research Site	Sofia	In reclutamento
Research Site	Sofia	Non ancora in reclutamento
Research Site	Sofia	Non ancora in reclutamento
Research Site	Yambol	Non ancora in reclutamento

Canada

Canada
Struttura	Città	Stato o regione	Stato
Research Site	Guelph	Ontario	Non ancora in reclutamento
Research Site	Montreal	Quebec	In reclutamento
Research Site	Saint-Charles-Borromée	Quebec	In reclutamento
Research Site	Sarnia	Ontario	In reclutamento
Research Site	Scarborough Village	Ontario	In reclutamento
Research Site	Stouffville	Ontario	In reclutamento
Research Site	Toronto	Ontario	In reclutamento
Research Site	Toronto	Ontario	Non ancora in reclutamento
Research Site	Toronto	Ontario	In reclutamento
Research Site	Vancouver	British Columbia	In reclutamento

China

China
Struttura	Città	Stato
Research Site	Changsha	Non ancora in reclutamento
Research Site	Changsha	Non ancora in reclutamento
Research Site	Hefei	Non ancora in reclutamento
Research Site	Hefei	Non ancora in reclutamento
Research Site	Huai'an	Non ancora in reclutamento
Research Site	Langfang	Non ancora in reclutamento
Research Site	Liangyugang	Non ancora in reclutamento
Research Site	Luoyang	Non ancora in reclutamento
Research Site	Nanjing	Non ancora in reclutamento
Research Site	Nanyang	Non ancora in reclutamento
Research Site	Pinggu	Non ancora in reclutamento
Research Site	Pingxiang	Non ancora in reclutamento

Nella scheda del registro sono indicati altri 159 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

9 settembre 2026
Centro aggiunto
8 sites added (209 total)
201209

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07662213